Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation

MYX.1 (MCRN-003) -- A Single Arm Phase II Study of High-Dose Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies -- was centrally activated March 29, 2016.

Centres wishing to participate on this trial should contact Gail McDonald, Study Coordinator, at

Please note that the MYX.1 website can not be accessed through our CCTG Clinical Trials Website. The trial website can be found at